"Our study suggests that, at least based on currently available gene delivery techniques, the expression of genetically encoded light sensors in retinal ganglion cells is likely a practical and advantageous strategy for optogenetic vision restoration."
"In experiments in rats and mice, two scientists -- an engineer and an ophthalmologist -- report the successful use of nanoparticles to deliver gene therapy for blinding eye disease. A uniquely engineered large molecule allows researchers to compact large bundles of therapeutic DNA to be delivered into the cells of the eye."
"Impressive new work from an international team of scientists has demonstrated a potential way to restore vision in those suffering from degenerative diseases of the retina. A single injection of nanoparticles was found to create a working artificial retina, restoring vision to blind rodents."
"SPVN06 is a breakthrough treatment for retinitis pigmentosa, an orphan inherited retinal disease which leads to blindness and affects nearly two million worldwide. SPVN06 uses a gene therapy-based approach independent of mutated genes and by a single subretinal injection of proprietary neurotrophic factors, aims at stopping and preventing the degeneration of photoreceptors leading to blindness."
This review aims at outlining the recent research efforts in identifying new drug targets for RP, especially focusing on the neuroprotective role of the Wnt/β-catenin/GSK3β pathway, apoptosis modulators (in particular PARP-1) but also on growth factors such as VEGF and BDNF. Furthermore, the role of spatiotemporally expressed GPCRs (GPR124) in the retina, and the emerging function of HDAC inhibitors in promoting retinal neuroprotection, will be discussed.
"On February 24, 2020, positive interim efficacy data from patients treated in the Phase 2a study were announced by the Company. The data continued to show a meaningful clinical effect from the therapy at all time-points out to twelve months post-treatment, as measured by the number of letters read on the ETDRS chart (the standardised eye chart used to measure visual acuity in clinical trials)."
"The new approach relies on photoactive polymeric nanoparticles that are one one hundredth of a diameter of human hair and behave like photovoltaic cells. These are suspended in a liquid and can be injected en masse under the retina. Once inside, they settle down and can then be used to electrically activate existing retinal neurons when light strikes the nanoparticles."
"Bionic Sight, LLC announced today that it has dosed the first patient in the Company’s Phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with Retinitis Pigmentosa. This is an important step toward bringing BS01 forward as a treatment to enable patients with retinal degenerative diseases to detect light, motion, and shapes, with the ultimate goal of restoring eyesight.
"Optogenetic proteins act essentially as converters; they receive light and convert it into neural signals. Bionic Sight’s therapy delivers the optogenetic proteins to the optic nerve, which sends the signals to the brain."
A Japanese health ministry panel on Thursday approved a clinical research program in which photoreceptor cells made from induced pluripotent stem, or iPS, cells will be transplanted into patients’ retinas in the world’s first attempt.
The program was proposed by Kobe City Eye Hospital, which is aiming to conduct the transplant later this fiscal year.
Subject to the clinical research are patients suffering from retinitis pigmentosa, an intractable eye disease for which there is no fundamental treatment.
Filed patent from Johns Hopkins University -"Included 3D retinal tissue generated in a laboratory. The 3D retinal tissue is coupled to an engineered microelectronic chip. The 3D retinal tissue together with the engineered microelectronic chip enable retinal regeneration and vision restoration for patients with retinal cell damage."